AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35441485 — intervention group
Group type: COMPARATOR
Intervention: Conventional orthopedic care group (n=65)
Number of subjects: 128
Study 35441485 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive orthopedic care group (n=63)
Number of subjects: 128
Study 33114457 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based mental health program, eight sessions, details on dosage and duration not specified.
Number of subjects: 0
Study 33075332 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylergonovine
Number of subjects: 284
Study 33075332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study 33324593 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid exposure during tuberculosis preventive treatment (IPT)
Number of subjects: 985
Study 33324593 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-B vitamin therapy (containing 300 mg nicotinamide daily) and isoniazid cessation
Number of subjects: 985
Study 33324593 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of niacin metabolites (1-methylnicotinamide and l-methyl-2-pyridone-5-carboxamide) in urine
Number of subjects: 985
Study 36333751 — intervention group
Group type: EXPERIMENTAL
Intervention: Early stellate ganglion block (e-SGB)
Number of subjects: 228
Study 36333751 — intervention group
Group type: COMPARATOR
Intervention: Camouflaging action before anesthesia induction (Control)
Number of subjects: 228
Study 34145993 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (0.2 μg/kg/min for 24 hours)
Number of subjects: 180
Study 34145993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 35612664 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics signature based on 12 features extracted from preoperative contrast-enhanced CT imaging.
Number of subjects: 204
Study 35612664 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram incorporating significant pathological predictors and radiomics signatures.
Number of subjects: 204
Study 33203462 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management from hospital discharge up to 2 years thereafter
Number of subjects: 0
Study 33203462 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 0
Study 33203462 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management
Number of subjects: 0
Study 34885211 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 504
Study 34885211 — intervention group
Group type: COMPARATOR
Intervention: No radiotherapy
Number of subjects: 504
Study 34885211 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous DS
Number of subjects: 504
Study 32259835 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive support intervention (resistance exercise training and individual dietary counseling)
Number of subjects: 82
Study 32259835 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate support intervention (resistance exercise training and nutrition course)
Number of subjects: 82
Study 32259835 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual dietitian consultations
Number of subjects: 82
Study 32259835 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition course
Number of subjects: 82
Study 32259835 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall intervention
Number of subjects: 82
Study 32259835 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate support intervention
Number of subjects: 82
Study 32259835 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive support intervention
Number of subjects: 82
Study 35991268 — intervention group
Group type: EXPERIMENTAL
Intervention: RUSH process (Group-A, n=52)
Number of subjects: 100
Study 35991268 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group-B, n=48)
Number of subjects: 100
Study 34349488 — intervention group
Group type: EXPERIMENTAL
Intervention: FAR + SOC
Number of subjects: 68
Study 34349488 — intervention group
Group type: COMPARATOR
Intervention: SOC
Number of subjects: 68
Study 35460070 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-based screening (HPV Arm) at 48-month intervals
Number of subjects: 111
Study 35460070 — intervention group
Group type: COMPARATOR
Intervention: Cytology (Cytology Arm) at 24-month intervals
Number of subjects: 111
Study 33243239 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted cortisol (based on 6 SNPs from CORNET)
Number of subjects: 12597
Study 33243239 — intervention group
Group type: COMPARATOR
Intervention: Genetically predicted IHD, ischemic stroke, and T2DM
Number of subjects: 12597
Study 35270384 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education and Motor Control Exercises (PNE/MCE)
Number of subjects: 37
Study 35270384 — intervention group
Group type: COMPARATOR
Intervention: Core Stability Training (CST)
Number of subjects: 37
Study 33979354 — intervention group
Group type: EXPERIMENTAL
Intervention: Omentin A326T (rs2274907) SNP
Number of subjects: 1886
Study 33979354 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating adiponectin concentrations
Number of subjects: 1886
Study 33979354 — intervention group
Group type: COMPARATOR
Intervention: Adiponectin levels
Number of subjects: 1886
Study 32396131 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans Women Connected mobile app
Number of subjects: 16
Study 34406254 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Electromagnetic Field (PEMF) therapy applied at 50 Hz, 25 G intensity, 20 min/session
Number of subjects: 40
Study 34406254 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Electromagnetic Field (PEMF) therapy
Number of subjects: 40
Study 34406254 — intervention group
Group type: COMPARATOR
Intervention: Sham group (device turned off)
Number of subjects: 40
Study 32278684 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana users
Number of subjects: 51
Study 32278684 — intervention group
Group type: COMPARATOR
Intervention: Non-marijuana users
Number of subjects: 51
Study 35687846 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical parametric mapping (SPM) analysis of 1-dimensional (1D) force-time curves
Number of subjects: 32
Study 35687846 — intervention group
Group type: COMPARATOR
Intervention: Zero-dimensional (0D) analysis of peak force
Number of subjects: 32
Study 32929521 — intervention group
Group type: EXPERIMENTAL
Intervention: TMR+RFF
Number of subjects: 50
Study 32929521 — intervention group
Group type: EXPERIMENTAL
Intervention: TMR+RFF with modified reconstruction
Number of subjects: 50
Study 32929521 — intervention group
Group type: COMPARATOR
Intervention: pCRT
Number of subjects: 50
Study 32929521 — intervention group
Group type: EXPERIMENTAL
Intervention: TMR+RFF and pCRT
Number of subjects: 50
Study 32703200 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPOXIRI plus bevacizumab (BEV)
Number of subjects: 100
Study 32703200 — intervention group
Group type: COMPARATOR
Intervention: FOLFOXIRI plus bevacizumab (BEV)
Number of subjects: 100
Study 35870942 — intervention group
Group type: EXPERIMENTAL
Intervention: Video‐feedback Intervention to promote Positive Parenting and Sensitive Discipline (VIPP‐SD)
Number of subjects: 40
Study 35870942 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 40
Study 33999486 — intervention group
Group type: EXPERIMENTAL
Intervention: Vericiguat
Number of subjects: 4956
Study 33999486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4956
Study 32792250 — intervention group
Group type: EXPERIMENTAL
Intervention: IIV by MNP administered by healthcare worker (HCW)
Number of subjects: 100
Study 32792250 — intervention group
Group type: EXPERIMENTAL
Intervention: IIV by MNP self‐administered by study participants
Number of subjects: 100
Study 32792250 — intervention group
Group type: COMPARATOR
Intervention: IIV by intramuscular (IM) injection administered by HCW
Number of subjects: 100
Study 32792250 — intervention group
Group type: COMPARATOR
Intervention: Placebo by MNP administered by HCW
Number of subjects: 100
Study 35322156 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-score model for opioid overdose
Number of subjects: 1752380
Study 35322156 — intervention group
Group type: COMPARATOR
Intervention: Control group (4 controls per case of overdose)
Number of subjects: 1752380
Study 35851746 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepilex Lite®
Number of subjects: 0
Study 35851746 — intervention group
Group type: COMPARATOR
Intervention: Band-Aid®
Number of subjects: 0
Study 33870760 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical skin adhesive (TSA)
Number of subjects: 70
Study 33870760 — intervention group
Group type: COMPARATOR
Intervention: Nylon sutures (NSs)
Number of subjects: 70
Study 32386451 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD Assessment Test (CAT) questionnaire
Number of subjects: 1203
Study 32386451 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate logistic regression model based on CAT scores and socio-demographic/work-related factors
Number of subjects: 1203
Study 32386451 — intervention group
Group type: EXPERIMENTAL
Intervention: Another model including CAT breathlessness
Number of subjects: 1203
Study 34292180 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg preoperatively + 40 mg/day postoperatively (80/40-mg group)
Number of subjects: 112
Study 34292180 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 20 mg/day postoperatively (20-mg group)
Number of subjects: 112
Study 34292180 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 40 mg/day postoperatively (40-mg group)
Number of subjects: 112
Study 34292180 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin, hs-CRP, highly sensitive cardiac troponin T, Gensini score
Number of subjects: 112
Study 34239934 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic environment rehabilitation (4 weeks, 5 times a week for 30 minutes)
Number of subjects: 137
Study 34239934 — intervention group
Group type: COMPARATOR
Intervention: Gym rehabilitation (4 weeks, 5 times a week for 30 minutes)
Number of subjects: 137
Study 35453173 — intervention group
Group type: EXPERIMENTAL
Intervention: 60mg ketorolac
Number of subjects: 56
Study 35453173 — intervention group
Group type: COMPARATOR
Intervention: 80mg triamcinolone acetonide
Number of subjects: 56
Study 32804869 — intervention group
Group type: EXPERIMENTAL
Intervention: Iliac autograft (group I; n=30)
Number of subjects: 60
Study 32804869 — intervention group
Group type: COMPARATOR
Intervention: Femoral autograft (group II; n=30)
Number of subjects: 60
Study 32415684 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 300 mg single dose
Number of subjects: 0
Study 32415684 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg once daily
Number of subjects: 0
Study 32415684 — intervention group
Group type: COMPARATOR
Intervention: Selexipag 200 μg twice daily
Number of subjects: 0
Study 32930620 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbapenem-resistant Enterobacteriaceae (CRE) infection
Number of subjects: 0
Study 32930620 — intervention group
Group type: COMPARATOR
Intervention: Carbapenem-susceptible Enterobacteriaceae (CSE)
Number of subjects: 0
Study 32930620 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for CRE infection
Number of subjects: 0
Study 35355656 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine (6 μg/mL) infused at 60 mL/h
Number of subjects: 62
Study 35355656 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine (75 μg/mL) infused at 60 mL/h
Number of subjects: 62
Study 35355656 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine and Phenylephrine
Number of subjects: 62
Study 34229451 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Native Enhancement (VNE)
Number of subjects: 1348
Study 32480319 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application access (CBT)
Number of subjects: 75
Study 32480319 — intervention group
Group type: COMPARATOR
Intervention: No mobile application access (Control)
Number of subjects: 75
Study 35254839 — intervention group
Group type: EXPERIMENTAL
Intervention: IV nicotine (0.0125, 0.025, 0.05, 0.1, or 0.2 mg/70 kg)
Number of subjects: 34
Study 35254839 — intervention group
Group type: EXPERIMENTAL
Intervention: IV nicotine (0.2 mg)
Number of subjects: 34
Study 35254839 — intervention group
Group type: EXPERIMENTAL
Intervention: IV nicotine (0.1 mg)
Number of subjects: 34
Study 35254839 — intervention group
Group type: COMPARATOR
Intervention: saline (placebo)
Number of subjects: 34
Study 33474960 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing
Number of subjects: 116
Study 33474960 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing combined with 3M Cavilon No-Sting Barrier Film
Number of subjects: 116
Study 32275361 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiaoshen acupuncture (acupuncture for regulating the spirit) applied in the observation group, including additional acupoints Baihui (GV 20), Shenting (GV 24), and Benshen (GB 13). Treatment given once a day, 6 times a week, for 3 weeks.
Number of subjects: 60
Study 32275361 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture at lower limbs' acupoints (Zusanli (ST 36), Yanglingquan (GB 34), and Xuanzhong (GB 39)) applied in the control group. Treatment given once a day, 6 times a week, for 3 weeks.
Number of subjects: 60
Study 33882347 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesion network mapping with white matter hyperintensities (WMHs)
Number of subjects: 164
Study 33019332 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalization using root mean square (RMS) value
Number of subjects: 60
Study 33019332 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalization using mean value (DIMean)
Number of subjects: 60
Study 33019332 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalization using maximum (DIPBI)
Number of subjects: 60
Study 33019332 — intervention group
Group type: COMPARATOR
Intervention: DI without normalization
Number of subjects: 60
Study 33019332 — intervention group
Group type: EXPERIMENTAL
Intervention: DIRMS
Number of subjects: 60
Study 35877084 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC plus docetaxel
Number of subjects: 690
Study 35877084 — intervention group
Group type: COMPARATOR
Intervention: SOC
Number of subjects: 690
Study 32524230 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra virgin olive oil
Number of subjects: 20
Study 32524230 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified refined olive oil
Number of subjects: 20
Study 32524230 — intervention group
Group type: EXPERIMENTAL
Intervention: Flax oil
Number of subjects: 20
Study 32524230 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapeseed oil
Number of subjects: 20
Study 32524230 — intervention group
Group type: COMPARATOR
Intervention: Control (basal urine)
Number of subjects: 20
Study 35347080 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated continuous monitoring alert to initiate postextubation RT‐driven care
Number of subjects: 201
Study 32412916 — intervention group
Group type: EXPERIMENTAL
Intervention: Binaural beats stimulation with frequencies of 256 Hz in one ear and 260 Hz in the opposite ear (intervention group)
Number of subjects: 40
Study 32412916 — intervention group
Group type: COMPARATOR
Intervention: Acoustical stimulation at 256 Hz in both ears (control group)
Number of subjects: 40
Study 32412916 — intervention group
Group type: EXPERIMENTAL
Intervention: Binaural beats stimulation
Number of subjects: 40
Study 33951339 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg CBD twice daily with 200 mg caffeine on day 26
Number of subjects: 16
Study 33951339 — intervention group
Group type: COMPARATOR
Intervention: Placebo with 200 mg caffeine on day 1
Number of subjects: 16
Study 35086348 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 1 mg
Number of subjects: 440
Study 35086348 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg
Number of subjects: 440
Study 35086348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 440
Study 33236840 — intervention group
Group type: EXPERIMENTAL
Intervention: Periconceptional iron supplementation
Number of subjects: 180
Study 33236840 — intervention group
Group type: COMPARATOR
Intervention: Control (no periconceptional iron supplementation)
Number of subjects: 180
Study 33236840 — intervention group
Group type: EXPERIMENTAL
Intervention: Active placental malaria
Number of subjects: 180
Study 33236840 — intervention group
Group type: EXPERIMENTAL
Intervention: Child body iron stores
Number of subjects: 180
Study 33236840 — intervention group
Group type: EXPERIMENTAL
Intervention: Chorioamnionitis
Number of subjects: 180
Study 35633196 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (20 mg/kg PO)
Number of subjects: 9
Study 35633196 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (30 mg/kg PO)
Number of subjects: 9
Study 35633196 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylbutazone (2.2 mg/kg PO)
Number of subjects: 9
Study 35633196 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo (C)
Number of subjects: 9
Study 33819279 — intervention group
Group type: EXPERIMENTAL
Intervention: Snorkel mask
Number of subjects: 56
Study 33819279 — intervention group
Group type: COMPARATOR
Intervention: FFP3 respirator mask
Number of subjects: 56
Study 33819279 — intervention group
Group type: COMPARATOR
Intervention: FFP3 mask
Number of subjects: 56
Study 32907603 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent implementation strategy including training and point-of-service tools (e.g., desktop chart with prompts for offering brief counseling)
Number of subjects: 52
Study 32907603 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral system available in arm 2
Number of subjects: 52
Study 36416492 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin (0.143 mg/kg)
Number of subjects: 16
Study 36416492 — intervention group
Group type: COMPARATOR
Intervention: Placebo (microcrystalline cellulose)
Number of subjects: 16
Study 33212068 — intervention group
Group type: EXPERIMENTAL
Intervention: CYD‐TDV (tetravalent dengue vaccine)
Number of subjects: 3967
Study 33212068 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoassays (EUROIMMUN, Panbio, TELL ME FAST, SD BIOLINE, OnSite)
Number of subjects: 3967
Study 32771996 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and ticagrelor for 3 months
Number of subjects: 68
Study 32771996 — intervention group
Group type: COMPARATOR
Intervention: Aspirin and clopidogrel for 3 months
Number of subjects: 68
Study 32771996 — intervention group
Group type: COMPARATOR
Intervention: Patients without HPR continued on aspirin and clopidogrel
Number of subjects: 68
Study 32771996 — intervention group
Group type: COMPARATOR
Intervention: Bioprosthetic valves (BEV, SEV, other)
Number of subjects: 68
Study 34797205 — intervention group
Group type: COMPARATOR
Intervention: Real GSM 900 MHz mobile phone exposure (pulse modulated at 217 Hz, mean power of 250 mW and 2 W peak, with a maximum specific absorption rate of 0.70 W/kg on 1 g tissue)
Number of subjects: 21
Study 34797205 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 21
Study 34004172 — intervention group
Group type: EXPERIMENTAL
Intervention: HEBC intervention
Number of subjects: 1451
Study 32729231 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative education
Number of subjects: 52
Study 32729231 — intervention group
Group type: COMPARATOR
Intervention: Traditional didactic education
Number of subjects: 52
Study 35843242 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisocabtagene maraleucel (liso-cel)
Number of subjects: 0
Study 35843242 — intervention group
Group type: COMPARATOR
Intervention: Standard of care with salvage chemotherapy followed by autologous stem cell transplantation
Number of subjects: 0
Study 32668475 — intervention group
Group type: EXPERIMENTAL
Intervention: hamstrings stretching plus whole-body vibration [S+WBV]
Number of subjects: 11
Study 32668475 — intervention group
Group type: EXPERIMENTAL
Intervention: partial-body cryotherapy [Cryo]
Number of subjects: 11
Study 32668475 — intervention group
Group type: COMPARATOR
Intervention: rest [Control]
Number of subjects: 11
Study 32361928 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid group (received periarticular infiltration of ropivacaine, epinephrine, and dexamethasone)
Number of subjects: 0
Study 32361928 — intervention group
Group type: COMPARATOR
Intervention: Control group (received periarticular infiltration of ropivacaine and epinephrine, without dexamethasone)
Number of subjects: 0
Study 32487965 — intervention group
Group type: EXPERIMENTAL
Intervention: TIDieR checklist adherence
Number of subjects: 141
Study 32487965 — intervention group
Group type: COMPARATOR
Intervention: TIDieR publication
Number of subjects: 141
Study 32487965 — intervention group
Group type: COMPARATOR
Intervention: Trial registration
Number of subjects: 141
Study 36286254 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (2.5 mg 3 times daily plus 2.5 mg as needed, max 20 mg daily)
Number of subjects: 1000
Study 36286254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study 36286254 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 1000
Study 33929674 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal Feedback (NF)
Number of subjects: 10
Study 33929674 — intervention group
Group type: COMPARATOR
Intervention: Random Feedback (RF)
Number of subjects: 10
Study 33402165 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing 30 min of total physical activity (PA)
Number of subjects: 1564
Study 33402165 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing 30 min of moderate-to-vigorous physical activity (MVPA)
Number of subjects: 1564
Study 33402165 — intervention group
Group type: EXPERIMENTAL
Intervention: Reallocating 30 min of inactive time to MVPA
Number of subjects: 1564
Study 34311783 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory facilitation technique performed for about three minutes, repeated for a total of 4/6 times in sequence, three times a day until spontaneous respiratory activity is achieved.
Number of subjects: 0
Study 34311783 — intervention group
Group type: COMPARATOR
Intervention: Individualized postural care program including respiratory facilitation and autogenous drainage.
Number of subjects: 0
Study 32096852 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated breast MRI
Number of subjects: 1444
Study 32096852 — intervention group
Group type: COMPARATOR
Intervention: Digital breast tomosynthesis (DBT)
Number of subjects: 1444
Study 35422240 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 144